Cancer Research UK and Guardant Health, Inc. announced a collaboration to explore the sharing of technologies, data, and insights to advance the development and precision of cancer detection and treatment. The agreement will enable the parties to discuss opportunities for collaboration to support the charity?s research and clinical development activities, focusing primarily on its clinical trials run by its Centre for Drug Development. This includes the DETERMINE trial ?

the first UK national precision medicine trial in rare cancers, and other Cancer Research UK and Cancer Research Horizons research collaborations. Additional potential collaboration activities may include sharing data and samples from the Cancer Research UK-funded research network to further develop and validate Guardant?s technologies, as well as explore other projects to accelerate the discovery and development of cancer drugs and diagnostics. Through this partnership, Guardant Health will further expand its partnership with one of the world?s leading cancer charities, Cancer Research UK, combining leading edge technology in biotechnology with an expansive reach of more than 200 clinical trials and studies in over a million people in the UK.